Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Coherus Oncology, Inc. (NASDAQ: CHRS)
CHRS Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
8.60%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%
CHRS Stock Analysis
CHRS
PE Ratio:
0.9
CHRS
PEG Ratio:
Not Available
CHRS
Forward EPS Growth (12 month):
0.00%
CHRS
PS Ratio:
3.8
CHRS
PSG Ratio:
0.1
CHRS
Forward Revenue Growth (12 month):
40.60%
CHRS Articles
No data was found